Moleac is pleased to announce the release of the CHIMES-E study results published online in the journal Cerebrovascular Diseases. It provides convincing data on NeuroAiD which confirm its persistent long-term benefits on patients recovery after an ischemic stroke.
These results have been presented at ESOC in Glasgow and ESC in Vienna. as part of the Scientific Program during the Clinical Trial session.
Moleac has developed the first product that helps patients to recover faster and better from their stroke disabilities.
Access detailed information on NeuroAiD™ by clicking HERE
Moleac’s Multi-Modal Approach to Treatment for Brain Injuries
Advances in research in the field of brain injury, like stroke, trauma and global ischemia, has never been more exciting and encouraging for the prospect of discovering novel effective treatments.
The conventional approach to research in acute treatment to develop one molecule targeted at one specific process in the pathway of one particular disease has failed in many consecutive clinical trials. Moleac takes on a multi-model strategy in its approach to drug development.
What is Stroke?
Stroke is a devastating disease affecting 17 million victims worldwide. It is a leading cause of adult acquired disability in many countries. Stroke is a medical emergency. Do not wait! The longer a patient waits, the more damage happens to the brain. After a stroke, an estimated 2 million brain cells, called neurons, die every minute without treatment.
Moleac aims at becoming a leading destination of choice for both experienced executives looking for new perspectives and young, ambitious talents looking to pave their careers in an innovative, dynamic and international company.
If you are talented and ready for new challenges, discover what Moleac has to offer you.